Opinion|Videos|December 18, 2024
The Post–CAR T Journey: Long-Term Monitoring, Multidisciplinary Care, and Continuous Patient Support
Panelists discuss how health care centers provide comprehensive long-term monitoring and support services for both patients receiving CAR T and their caregivers in the posttreatment period, including regular medical assessments and ongoing educational resources.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What specific long-term monitoring protocols and support services does your center provide for patients undergoing CAR T and their caregivers in the months and years following treatment (eg, monitoring and care, support services, caregiver education, etc)?
Advertisement
Related to this article
Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA MCGP Panel Votes in Favor of the Galleri Multicancer Early Detection Test
2
FDA Grants Approval to Lirafugratinib for Advanced Cholangiocarcinoma with FGFR2 Alteration
3
Approaching Cardiovascular Risk in Prostate Cancer Hormonal Therapy
4
Emerging Endocrine Doublets and Serial ESR1 Testing in HR+/HER2− mBC
5